# A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06130553/  
OnCo record `nct06130553` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD3470 and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.

## Summary

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2026-08-27: recruiting. Enrollment is planned at 334 participants. Primary completion is estimated at 2028-12-04. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: AZD3470, Datopotamab deruxtecan. Registered primary measures: All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents; Module 1: Incidence of dose-limiting toxicities (DLT); Module 2: Progression Free Survival assessed by the Investigator according to RECIST v1.1.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: PRIMROSE
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06130553
- Phase: 1/2
- Setting: A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
- Sponsor: AstraZeneca
- Enrolled: 334

## Notes

- ClinicalTrials.gov record last updated 2026-08-27: recruiting. Enrollment is planned at 334 participants. Primary completion is estimated at 2028-12-04. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT06130553: https://clinicaltrials.gov/study/NCT06130553

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [AZD3470](https://onco.cc/drugs/azd3470/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06130553.json